

Special Issue

Recent Advances of Receptor Tyrosine Kinases in Solid Tumors

Message from the Guest Editor

This Special Issue, "Recent Advances of Receptor Tyrosine Kinases in Solid Tumors", will mainly focus on the role of new therapies targeting Receptor Tyrosine Kinases and their downstream signaling in solid tumors. Receptor tyrosine kinases (RTKs) are a large family of receptors with similar structures. RTKs are crucial targets for treating cancer. Since 2000, when the first tyrosine kinase inhibitor (TKI), imatinib, was approved to target multiple RTKs, three generations of TKIs have been developed. They have been involved in significant progress in the personalized treatment of cancer during the past twenty years. TKIs are approved for several solid tumors, especially against epidermal growth factor receptors (EGFR) in patients with non-small cell lung cancer (NSCLC) and against HER2 in metastatic and Her2-positive breast cancer. TKIs, combined with other targeted therapies, chemotherapy, or immunotherapy, have been recommended to address these issues. I invite authors to submit original research and review articles focusing on the biological functions and therapeutic potential, highlighting the future direction of RTK signaling in solid tumors.

Guest Editor

Dr. Parham Jabbarzadeh Kaboli

Graduate Institute of Biomedical Sciences, China Medical University,
Taichung 40402, Taiwan

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/162368

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).